{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:21:07Z","timestamp":1790490067908,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":536,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin de l'Acad\u00e9mie Nationale de M\u00e9decine"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.banm.2020.07.052","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T02:37:39Z","timestamp":1595385459000},"page":"884-889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Actualit\u00e9s th\u00e9rapeutiques et innovations dans les maladies syst\u00e9miques et auto-immunes"],"prefix":"10.1016","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6463-2160","authenticated-orcid":false,"given":"L.","family":"Guillevin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.banm.2020.07.052_bib0115","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-200203000-00004","article-title":"Systemic sclerosis: demographic, clinical, and serologic features and survival in 1012\u00a0Italian patients","volume":"81","author":"Ferri","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.banm.2020.07.052_bib0120","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","article-title":"Treatment of pulmonary arterial hypertension","volume":"351","author":"Humbert","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.banm.2020.07.052_bib0125","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.banm.2020.07.052_bib0130","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.banm.2020.07.052_bib0135","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.banm.2020.07.052_bib0140","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: a review in systemic lupus erythematosus","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.banm.2020.07.052_bib0145","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus. The randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.banm.2020.07.052_bib0150","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.banm.2020.07.052_bib0155","doi-asserted-by":"crossref","first-page":"e000163","DOI":"10.1136\/lupus-2016-000163","article-title":"Off-label use of rituximab for systemic lupus erythematosus in Europe","volume":"3","author":"Ryd\u00e9n-Aulin","year":"2016","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.banm.2020.07.052_bib0160","series-title":"B cell therapies: how the past informs the future, American College of Rheumatology Annual Meeting, Atlanta","author":"Isenberg","year":"2019"},{"key":"10.1016\/j.banm.2020.07.052_bib0165","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3\u00a0trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.banm.2020.07.052_bib0170","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"issue":"Suppl.\u00a082","key":"10.1016\/j.banm.2020.07.052_bib0175","first-page":"S11","article-title":"Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF-\u03b1 and IL-6\u00a0receptor targeted therapies in refractory Takayasu arteritis","volume":"32","author":"Youngstein","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.banm.2020.07.052_bib0180","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.autrev.2018.01.019","article-title":"Non-glucocorticoid drugs for the treatment of Takayasu's arteritis: a systematic review and meta-analysis","volume":"17","author":"Barra","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.banm.2020.07.052_bib0185","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.banm.2020.07.052_bib0190","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.banm.2020.07.052_bib0195","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/rheumatology\/kez091","article-title":"Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis","volume":"58","author":"Adler","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.banm.2020.07.052_bib0200","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial","volume":"134","author":"Jover","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.banm.2020.07.052_bib0205","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.banm.2020.07.052_bib0210","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.banm.2020.07.052_bib0215","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.banm.2020.07.052_bib0110","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Bulletin de l'Acad\u00e9mie Nationale de M\u00e9decine"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001407920304386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001407920304386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:59:04Z","timestamp":1757545144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001407920304386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0001407920304386"],"URL":"https:\/\/doi.org\/10.1016\/j.banm.2020.07.052","relation":{},"ISSN":["0001-4079"],"issn-type":[{"value":"0001-4079","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Actualit\u00e9s th\u00e9rapeutiques et innovations dans les maladies syst\u00e9miques et auto-immunes","name":"articletitle","label":"Article Title"},{"value":"Bulletin de l'Acad\u00e9mie Nationale de M\u00e9decine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.banm.2020.07.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 l'Acad\u00e9mie nationale de m\u00e9decine. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}